Literature DB >> 8789046

Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods.

P C Mehaffey1, S D Putnam, M S Barrett, R N Jones.   

Abstract

The macrolide-azilide susceptibility testing (agar dilution, disk diffusion, Etest) criteria for 105 Neisseria gonorrhoeae strains were evaluated. In addition, the potencies of azithromycin, clarithromycin, and erythromycin were studied. The most active macrolide-azilide agent was azithromycin (MIC at which 90% of the isolates are inhibited [MIC90], 0.5 microgram/ml) compared with clarithromycin (MIC90, 1.5 to 2 micrograms/ml) and erythromycin (MIC90, 2 to 4 micrograms/ml). The Etest (AB Biodisk, Solna, Sweden) was observed to produce MIC results very similar to those of the reference agar dilution test (GC agar base), with 100% of the results within 1 log2 dilution step of the reference MICs. The disk diffusion test zone diameters for all three drugs correlated at an acceptable level (r = -0.81 to -0.92) with the reference agar dilution MICs. Interpretive criteria for susceptibility were proposed for azithromycin at a MIC of < or = 2 micrograms/ml and a disk diffusion test zone of > or = 25 mm. No category for resistance was proposed because of the paucity of strains for which MICs were > 2 micrograms/ml. These tentative criteria should be further validated by correlations with clinical trial data for gonococcal strains (as they emerge) that have azithromycin MICs above the proposed susceptible category range.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8789046      PMCID: PMC228828          DOI: 10.1128/jcm.34.2.479-481.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species.

Authors:  A Lassus
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

2.  In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

3.  Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group.

Authors:  H H Handsfield; Z A Dalu; D H Martin; J M Douglas; J M McCarty; D Schlossberg
Journal:  Sex Transm Dis       Date:  1994 Mar-Apr       Impact factor: 2.830

4.  E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates.

Authors:  J H Hughes; D J Biedenbach; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

5.  High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan.

Authors:  M Tanaka; J Kumazawa; T Matsumoto; I Kobayashi
Journal:  Genitourin Med       Date:  1994-04

6.  Treatment of gonococcal urethritis in men with a rifampicin-erythromycin combination.

Authors:  J D Oriel; G L Ridgway; D Goldmeier; D Felmingham
Journal:  Sex Transm Dis       Date:  1982 Oct-Dec       Impact factor: 2.830

7.  Clinical toleration and safety of azithromycin.

Authors:  S Hopkins
Journal:  Am J Med       Date:  1991-09-12       Impact factor: 4.965

Review 8.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy.

Authors:  T Fekete
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

9.  Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men.

Authors:  O Steingrímsson; J H Olafsson; H Thórarinsson; R W Ryan; R B Johnson; R C Tilton
Journal:  Sex Transm Dis       Date:  1994 Jan-Feb       Impact factor: 2.830

10.  Comparison of E test with agar dilution for antimicrobial susceptibility testing of Neisseria gonorrhoeae.

Authors:  E Van Dyck; H Smet; P Piot
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

View more
  5 in total

1.  Emergence of fluoroquinolone resistance in Neisseria gonorrhoeae isolates from four clinics in three regions of Kenya.

Authors:  Philippe R S Lagace-Wiens; Sarah Duncan; Joshua Kimani; Alexander Thiong'o; Juma Shafi; Scott McClelland; Eduard J Sanders; George Zhanel; Nicholas Muraguri; Supriya D Mehta
Journal:  Sex Transm Dis       Date:  2012-05       Impact factor: 2.830

Review 2.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: investigation using 510(k) review criteria, recommended by the Food and Drug Administration.

Authors:  D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

Review 4.  On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections.

Authors:  R Matthew Chico; Berkin B Hack; Melanie J Newport; Enesia Ngulube; Daniel Chandramohan
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11-06       Impact factor: 5.091

5.  Comparison of two disc diffusion methods with minimum inhibitory concentration for antimicrobial susceptibility testing of Neisseria gonorrhoeae isolates.

Authors:  P Khaki; A Sharma; P Bhalla
Journal:  Ann Med Health Sci Res       Date:  2014-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.